Management of mTOR Inhibitor Side Effects in Breast Cancer
Published Online: Wednesday, June 19, 2013
For High-Definition, ClickManaging the side effects associated with mTOR inhibition is a novel endeavor for many breast oncologists. As such, they must grow familiar with techniques for managing these unique side effects. Along these lines, Andrew D. Seidman, MD, recommends a work published by his colleague Mario E. Lacouture, MD, on the management of dermatologic issues associated with mTOR inhibition.
To avoid unwarranted side effects and optimize response to treatment, researchers are exploring correlative markers that predict response to mTOR inhibition. A few studies examining these markers were presented at the 2013 ASCO Annual Meeting, Hope S. Rugo, MD, notes. Markers are intriguing to most members of the panel, Edith A. Perez, MD, suggests. However, it is important that large data sets are utilized to identify and validate new markers, particularly to avoid inaccurate findings.
The management of mTOR inhibitor-induced hypertriglyceridemia is a novel undertaking for some breast oncologists, Seidmen believes. Fortunately, downstream effects, such as pancreatitis, do not commonly manifest but the management of this side effect, as well as hyperglycemia, warrants the awareness of treating physicians. As further trials exploring everolimus in breast cancer are completed, such as BOLERO-3, the management of these unique side effects grows more important, notes Adam M. Brufsky, MD, PhD.
View More From This Discussion
Managing the side effects associated with mTOR inhibition is a novel endeavor for many breast oncologists. As such, in this segment, the panelists explore the side effects that warrant enhanced awareness and the markers being explore to predict response, in order to avoid unwarranted side effects.
View Episode >>>
View Episode >>>
Sara Hurvitz, MDAssistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Edith A. Perez, MDDeputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Andrew D. Seidman, MDProfessor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Online CME Activities
Most Popular Right Now
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.